Digestive system with antipsychotic therapy (literature review) Part VI: iatrogenic liver pathology (effect of atypical antipsychotics)
Abstract
The antipsychotic preparations which are widely used in medical practice possess an extensive range of the negative side effects including operating on organs of system of digestion. In the final part of the offered review the pathology of the liver associated with reception of separate concrete antipsychotic medicines of the second generation is considered.
References
1. A case report of olanzapine-induced hypersensitivity syndrome / A. Raz, R. Bergman, O. Eilam [et al.] // Am. J. Med. Sci.-2001.- Vol. 321, N2.- P. 156-158. doi: 10.1097/00000441-200102000-00008.
2. A comparison of ziprasidone and risperidone in the long-term treatment of schizophrenia: a 44-week, double-blind, continuation study / D. E. Addington, A. Labelle, J. Kulkarni [et al.] // Can. J. Psychiatry.- 2009.- Vol. 54, N 1.- P. 46-54. doi: 10.1177/070674370905400108.
3. A review of liver function tests during treatment with atypical antipsychotic drugs: a chart review study / N. Atasoy, A. Erdogan, I. Yalug [et al.] // Prog. Neuropsychopharmacol. Biol. Psychiatry.- 2007.- Vol. 31, N6.- P. 1255-1260. doi: 10.1016/j.pnpbp.2007.05.005.
4. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study / M. Arato, R. O'Connor, H. Y. Meltzer[et al] / / Int. Clin. Psychopharmacol. - 2002.- Vol. 17, N5.- P. 207-215.
5. Acute cholestatic hepatitis probably associated with risperidone / F. Llinares Tello, C. Hernandez Prats, N. Bosacoma Ros[et al.] // Int. J. Psychiatry Med.- 2005.- Vol. 35, N2.- P. 199-205. doi: 10.2190/5XRB-D 2XX-X8AH-32KB.
6. Acute drug-induced hepatitis during aripiprazole monotherapy: a case report / J. Kornischka, J. Cordes, C. Engelke [et al.] / / J. Pharmacovigil.- 2016.- Vol. 4, N2.- Art. 201. doi:10.4172/2329-6887.1000201.
7. [Acute hepatocellular lesion after successive exposure to clozapine and olanzapine in a patient with chronic hepatitis C infection] / R. Gomez Espn, I. Sanchez Quiles, H. Hallal[et al.] / / Gastroenterol. Hepatol.-2009.- Vol. 33, N2.- P. 150-152. doi: 10.1016/j.gastrohep.2009.08.001
8. Akta$ S, Bakir M. G.T., Kaya B. Toxic hepatitis development due to clozapine treatment for schizophrenia: case presentation // Turk. J. Psychiatry.- 2015.- Vol. 26, Suppl 1.- Р. 47.
9. Al Mutairi F., Dwivedi G., Al Ameel T. Fulminant hepatic failure in association with quetiapine: a case report // J. Med. Case Rep.- 2012.- Vol. 6, N 1.- P. 418. doi: 10.1186/1752-1947-5^18.
10. Antipsychotic Agents. [Электронный ресурс].- URL: http://livertox.nih.gov/AntipsychoticAgents. htm (дата обращения: 15.10.2016).
11. Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications / C. Tek, S. Kucukgoncu, S. Guloksuz [et al.] // Early Interv. Psychiatry.- 2015.- Vol. 10, N3.- P. 193-202. doi: 10.1111/eip.12251.
12. Aripiprazole. [Электронный ресурс].- URL: http://livertox.nlm.nih.gov/Aripiprazole.htm (дата обращения: 15.10.2016).
13. [Autoimmune hepatitis after risperidone-induced cholestatic hepatitis] / M. L. Legaz Huidobro, P. Gonzalez Carro, F. Perez Roldan [et al.] // Gastroenterol. Hepatol.- 2005.- Vol. 28, N3.- P. 135-136. doi: 10.1157/13072013.
14. AstraZeneca. Seroquel (quetiapine fumarate).- 2003. [Электронный ресурс].- URL: http://www. accessdata.fda.gov/drugsatfda_docs/la-bel/2009/022047s011s 016s017s019s022lbl.pdf. (дата обращения: 21.02.2016).
15. Balestrieri M., Vampini C., Bellantuono C. Efficacy and safety of novel antipsychotics: a critical review // Hum. Psychopharmacol.- 2000.- Vol. 15, N 7.- P. 499-512. doi: 10.1002/1099-1077(200010) 15:7<499:: AID-HUP194>3.0.C0; 2-3.
16. Beasley C.M. Jr., Tollefson G.D., Tran P. V. Safety of olanzapine // J. Clin. Psychiatry.- 1997.- Vol. 58, Suppl 10.- P. 13-17.
17. Benazzi F. Risperidone-induced hepatotoxicity // Pharmacopsychiatry.- 1998.- Vol. 31, N6.- P. 241. doi:10.1055/s-2007-979337.
18. Bile ductopenia following therapy with sulpiride / D. Villari, F. Rubino, F. Corica [et al.] // Virchows Arch.- 1995.- Vol. 427, N2.- P. 223-226.
19. Bristol-Myers Squibb. Abilify (aripiprazole): EMA summary of product characteristics.- 2016. [Электронный ресурс]. - URL: http://www. ema.europa.eu/docs/en_GB/document_library/ EPAR_-_Product_Information/human/ 000471/ WC500020170.pdf. (дата обращения: 15.02.2016).
20. Case study: risperidone-induced hepatotoxicity in pediatric patients / S. Kumra, D. Herion, L. K. Jacobsen [et al.] // J. Am. Acad. Child. Adolesc. Psychiatry.- 1997.- Vol. 36, N5.- P. 701-705. doi: 10.1097/00004583-199705000-00022.
21. Chaplin A. C., Curley M. A., Wanless I. R. Re: Recent case report of clozapine-induced acute hepatic failure: letter.- Can. J. Gastroenterol.- 2010.- Vol. 24, N 12.- P. 739-740.
22. Clozapine. [Электронный ресурс].- URL: http://livertox.nih.gov/Clozapine.htm (дата обращения: 15.10.2016).
23. [Clozapine-induced cholestatic jaundice: a case report] / G. Dorta, R Siebenmann, P. Fröhli [et al.] // Z. Gastroenterol.- 1989.- Vol. 27, N 7.- 388-390.
24. [Clozapine-induced cholestatic liver lesions. A case study] / G. Schmidt, G. Börsch, K.-M. Müller [et al.] // Dtsch. med. Wschr.- 1987.- Vol. 112.- P. 844-846. doi: 10.1055/s-2008-1068152.
25. Clozapine-induced fatal fulminant hepatic failure: a case report/ A. Chang, D.S. Krygier, N. Chatur[et al.] // Can. J. Gastroenterol.-2009.- Vol. 23, N5.- P. 376-378. doi: 10.1007/978-3-540-85705-1_38.
26. [Clozapine-induced toxic hepatitis] / J. T. Larsen, S. V. Clemensen, N. A. Klitgaard [et al.] // Ugeskr. Laeger.- 2001.- Vol. 163.- P. 2013-2014.
27. Clozapine-induced toxic hepatitis with skin rash / S. Y. Fong, K.L. Au Yeung, J. M. Tosh [etal.] // J. Psychopharmacol.- 2005.- Vol. 19, N 1.- P. 107. doi: 10.1177/0269881105047287.
28. Clozapine rechallenge after marked liver enzyme elevation: letter/ A. E. Eggert, M. L. Crismon, P. G. Dorson [et al.] // J. Clin. Psychopharmacol.- 1994.- Vol. 14, N6.- P. 425-426.
29. Clozapine toxicity and hepatitis / C. A. Brown, S. Telio, C.A. [etal.] // J. Clin. Psychopharmacol.- 2013.- Vol. 33, N4.- P. 570-571. doi: 10.1097/ JCP.0b013e3182946586.
30. Conley R. R., Meltzer H. Y. Adverse events related to olanzapine // J. Clin. Psychiatry.- 2000.- Vol. 61, Suppl 8.- P. 26-29.
31. Cordeiro Q. Jr., Elkis H. Pancreatitis and cholestatic hepatitis induced by risperidone: letter / / J. Clin. Psychopharmacol.- 2001.-Vol. 21, N5.- P. 529-530.
32. Dara L., Liu Z. X., Kaplowitz N. Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications // Liver Int.- 2016.- Vol. 36, N2.- P. 158-165. doi: 10.1111/liv.12988.
33. Double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia / H. Zhang, H. Li, L. Shu [et al] // Neuropsychiatr. Dis. Treat.- 2011.- Vol. 7, N 1.- P. 77-85. doi: 10.2147/NDT.S 16664.
34. Drug rash with eosinophilia and systemic symptoms (DRESS syndrome): letter / J. S. Gordon, K. M. Neyman, R. D. Wells [et al.] // Cutis.-2012.- Vol. 89, N4.- P. 180-182.
35. Drug-induced liver injury: hepatotoxicity of quetiapine revisited / A. Shpaner, W. Li, V. Ankoma- Sey[et al.] //Eur. J. Gastroenterol. Hepatol.- 2008.- Vol. 20, N 11.- P. 1106-1109. doi: 10.1097/ MEG.0b013e3282f8e3a0.
36. Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia / S. W. Kim, I. S. Shin, J. M. Kim [et al.] // Clin. Neuropharmacol.-2010.- Vol. 33, N3.- P. 121-125. doi: 10.1097/WNF.0b013e3181d52b85. Медицинский алфавит № 40 / 2017, том № 4. Практическая гастроэнтерология E-mail: medalfavit@mail.ru
37. Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia - a retrospective study of 387 patients / D. Naber, M. Leppig, R. Grohmann [et al.] // Psychopharmacology (Berl.).- 1989.- Vol. 99, Suppl- P. S73-S76.
38. El Hajj I., Sharara A.I,, Rockey D. C. Subfulminant liver failure associated with quetiapine // Eur. J. Gastroenterol. Hepatol.- 2004.- Vol. 16, N12.- P. 1415-1418.
39. European Medicines Agency. EPAR summary for the public: paliperidone.- 2015. [Электронный ресурс].- URL: http://www.ema.europa.eu/ docs/en_GB/ document_library/EPAR_-_Product_I nformation/human/0040 66/WC500180640. pdf. (дата обращения: 21.02.2016).
40. Fatal acute fulminant liver failure due to clozapine: a case report and review of clozapine-induced hepatotoxicity / B. Macfarlane, S. Davies, K. Mannan [et al.] / / Gastroenterology.- 1997.- Vol. 112, N5.- P. 1707-1709.
41. Fatal hepatotoxicity in an elderly patient receiving low-dose quetiapine / M. I. Naharci, N. Karadurmus, O. Demir [et al.] // Am. J. Psychiat.- 2011.- Vol. 168, N2.- P. 212-213. doi: 10.1176/ appi.ajp.2010.10091292.
42. Flanagan R. J. Side effects of clozapine and some other psychoactive drugs // Curr. Drug Saf.- 2008.- Vol. 3, N2.- P. 115-122. doi: 10.2174/157488608784529251.
43. Food and Drug Administration. Department of Health and Human Services. New molecular entity follow-up: aripiprazole.- 2008. [Электронный ресурс].- URL: http://www.fda.gov/down-loads/Drugs/DrugSafety/Post marketDrugSafety-InformationforPatientsandProviders/UCM185327. pdf. (дата обращения: 01.03.2016).
44. Food and Drug Administration. Psychopharmacology Drugs Advisory Committee. Briefing book: Serdolect (sertindole) tablets.-2009. [Электронный ресурс].- URL’ http://www.fda.gov/ohrms/ dockets/ac/09/briefing/ 2009-4424b1 -01 -FDA. pdf. (дата обращения: 20.03.2016).
45. Fuller M. A., Simon M. R., Freedman L. Risperidone-associated hepatotoxicity // J. Clin. Psychopharmacol.- 1996.- Vol. 16, N 1.- P. 84-85.
46. Gaertner H. J., Fischer E., Hoss J. Side effects of clozapine // Psychopharmacology (Berl.).- 1989.- Vol. 99, Suppl 1.- P. S 97-S 100.
47. Haberfellner E. M., Honsig T. Nonalcoholic steatohepatitis: a possible side effect of atypical antipsychotics // J. Clin. Psychiatry.- 2003.- Vol. 64, N7.- P. 851.
48. Hepatic encephalopathy associated with combined clozapine and divalproex sodium treatment / W. C. Wirshing, D. Ames, S. Bisheff [et al.] // J. Clin. Psychopharmacol.- 1997.- Vol. 17, N2.- P. 120-121.
49. Hepatic safety of atypical antipsychotics: current evidence and future directions / M. Slim, I. Medina-Caliz, A. Gonzalez-Jimenez [et al.] // Drug Saf.- 2016.- Vol. 39, N 10.- P. 925-943. doi: 10.1007/s40264-016-0436-7.
50. [Hepatic tolerance of atypical antipsychotic drugs] / G. Dumortier, W. Cabaret, L. Stamatiadis [et al.] // Encephale.- 2002.- Vol. 28, N 6, Pt 1.- P. 542-551.
51. Hepatitis, hyperglycemia, pleural effusion, eosinophilia, hematuria and proteinuria occurring early in clozapine treatment / J. Thompson, K. N. Chengappa, C. B. Good [et al.] // Int. Clin. Psychopharmacol.- 1998.- Vol. 13, N2.- P. 95-98.
52. Hepatotoxicity of clozapine / M. Hummer, M. Kurz, I. Kurzthaler[et al.] // J. Clin. Psychopharmacol.- 1997.- Vol. 17, N4.- P. 314-317.
53. Histological evaluation of the role of atypical antipsychotic drugs in inducing non-alcoholic fatty liver disease in adult male albino rats (light and electron microscopic study). / H. M. Soliman, H. M. Wagih, S. A. Algaidi [et al.] // Folia Biol. (Praha).- 2013.- Vol. 59, N5.- P. 173-180.
54. Hung C. C., Wei I. H., Huang C. C. Late-onset cholestatic hepatitis induced by olanzapine in a patient with schizophrenia // Prog. Neuropsycho-pharmacol. Biol. Psychiatry.-2009.- Vol. 33, N8.- P. 1574-1575. doi: 10.1016/j.pnpbp.2009.09.011.
55. Jadallah K. A., Limauro D. L., Colatrella A. M. Acute hepatocellular-cholestatic liver injury after olanzapine therapy // Ann. Intern. Med.- 2003.- Vol. 138, N4.- P. 357-358.
56. Kang S. H., Lee J. I. Eosinophilia, pleural effusion, hepatitis, and jaundice occurring early in clozapine treatment // Clin. Psychopharmacol. Neurosci. - 2013.- Vol. 11, N2.- P. 103-105. doi: 10.9758/cpn.2013.11.2.103.
57. Kolpe M., Ravasia S. Effect of olanzapine on the liver transaminases // Can. J. Psychiatry.- 2003.- Vol. 48, N 3.- P. 210. doi: 10.1177/070674370304800313.
58. Landau J., Martin A. Is liver function monitoring warranted during risperidone treatment? // J. Am. Acad. Child Adolesc. Psychiatry.- 1998.- Vol. 37, N 10.- P. 1007-1008.
59. Larry D., Ripault M. P. Hepatotoxicity of psychotropic drugs and drugs of abuse / / Drug-induced liver disease / N. Kaplowitz, L. D. DeLeve (eds.).- 3rd ed.- Amsterdam: Elsevier, 2013.- P. 447-462.
60. Lin C. H., Liu C.M., Huang W. L. Quetiapine-induced hepatocellular damage // Psychosomatics.- 2012.- Vol. 53, N6.- P. 601-602. doi: 10.1016/j.psym.2012.06.001.
61. [Liver cell necrosis during administration of clozapine] / J. E. Hovens, L. M. Vogtländer, H. A. Verhoeve [et al.] // Ned. Tijdschr. Geneeskd.- 1994.- Vol. 138, N7.- P. 363-365.
62. Liver function tests in children and adolescents receiving risperidone treatment for a year: a longitudinal, observational study from Turkey / M. G. Karaman, A. Erdogan, E. Tufan [et al.] // Int. J. Psychiatry. Clin. Pract.- 2011.- Vol. 15, N3.- P. 204-208. doi: 10.3109/13651501.2011.582537.
63. Liver toxicity due to olanzapine: letter / J. L. Dominguez-Jimenez, J. J. Puente-Gutierrez, E.M. Pelado-Garcia [et al.] // Rev. Esp. Enferm. Dig.- 2012.- Vol. 104, N 11.- P. 617-618. doi: 10.4321/S 1130-0108201200110001.
64. Luo D., McColl P., Walmsley R. Acute onset of ascites with clozapine-induced hepatitis // Intern. Med. J.- 2007.- Vol. 37, N3.- P. 204-205. doi:10.1111/j.1445-5994.2006.01300.x.
65. Mahapatra S, Belgrad J. L., Adeoye M. A. Psychotropic drug-related eosinophilia with systemic symptoms after acute caffeine ingestion // Pediatrics.- 2011.- Vol. 127, N 1.- P. e235-e238. doi: 10.1542/peds.2010-0374.
66. Management of clozapine-related hepatotoxicity / S. Keane, A. Lane, T. Larkin [et al.] // J. Clin. Psychopharmacol.- 2009.- Vol. 29, N6.- P. 606-607. doi: 10.1097/JCP.0b013e3181c163ef.
67. Management of marked liver enzyme increase during clozapine treatment: a case report and review of the literature / A. Erdogan, N. Kocabasoglu, I. Yalug [et al.] // Int. J. Psychiatry. Med.- 2004.- Vol. 34, N 1.- P. 83-89. doi: 10.2190/44WA-WXF7-3UHA-FDV1.
68. Management of marked liver enzyme increase during olanzapine treatment: a case report and review of the literature / P. Manceaux, E. Constant, N. Zdanowicz [et al.] // Psychiatr. Danub.- 2011.- Vol. 23, Suppl. 1.- S 15-S 17.
69. Markowitz J. S., Grinberg R., Jackson C. Marked liver enzyme elevations with clozapine // J. Clin. Psychopharmacol.- 1997.- Vol. 17, N 1.- P. 70-71.
70. Marwick K. F., Taylor M., Walker S. W. Antipsychotics and abnormal liver function tests: systematic review // Clin. Neuropharmacol.- 2012.- Vol. 35, N5.- P. 244-253. doi: 10.1097/ WNF.0b013e31826818b6.
71. McCormack P. L. Olanzapine: in adolescents with schizophrenia or bipolar I disorder // CNS Drugs.- 2010.- Vol. 24, N 5.- P. 443-452. doi: 10.2165/11204430-000000000-00000.
72. Melzer E., Knobel B. Severe cholestatic jaundice due to sulpiride // Isr. J. Med. Sci.- 1987.- Vol. 23, N 12.- P. 1259-1260.
73. Metabolic syndrome in people with schizophrenia: a review / M. DE Hert, V. Schreurs, D. Vancampfort [et al.] // World Psychiatry.- 2009.- Vol.8, N 1.- P. 15-22.
74. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions / L. Urichuk, T. I. Prior, S. Dursun [et al.] // Curr. Drug Metab.- 2008.- Vol. 9, N5.- P. 410-8.
75. Nasrallah H.A., Tandon R. Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia // J. Clin. Psychiatry.- 2002.- Vol. 63, Suppl 13.- Р. 12-20.
76. Naturalistic observation on the hepatic enzyme changes in patients treated with either risperi done or olanzapine alone / C. U. Pae, H. K. Lim, T. S. Kim [et al.] // Int. Clin. Psychopharmacol.- 2005.- Vol. 20, N3.- P. 173-176.
77. Ohmoto K., Yamamoto S., Hirokawa M. Symptomatic primary biliary cirrhosis triggered by administration of sulpiride: letter // Am. J. Gastroenterol.- 1999.- Vol. 94, N 12.- P. 3660-3661. doi:10.1111/j.1572-0241.1999.01634.x
78. Olanzapine. [Электронный ресурс].- URL: http://livertox.nih.gov/Olanzapine.htm (дата обращения: 15.10.2016).
79. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial / G. D. Tollefson, C. M. Beasley Jr., P. V. Tran [et al.] // Am. J. Psychiatry.- 1997.- Vol. 154, N4.- P. 457-465. doi: 10.1176/ ajp.154.4.457.
80. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial / C. M. Beasley Jr., G. Tollefson, P. Tran [et al.] // Neuropsychopharmacology.- 1996.- Vol. 14, N2.- P. 111-123. doi: 10.1016/0893-133X(95)00069-P.
81. Olanzapine versus placebo: results of a doubleblind, fixed-dose olanzapine trial / C. M. Beasley Jr., T. Sanger, W. Satterlee [et al.] // Psychopharmacology.- 1996.- Vol. 124, N 1-2.- P. 159-167.
82. Paulzen M., Orfanos S., Gründer G. Remission of drug-induced hepatitis after switching from risperidone to paliperidone // Am. J. Psychiatry.- 2010.- Vol. 167, N3.- P. 351-352. doi: 10.1176/ appi.ajp.2009.09081243.
83. Phillips E. J., Liu B. A., Knowles S. R. Rapid onset of risperidone-induced hepatotoxicity // Ann. Pharmacother. - 1998.- Vol. 32, N7-8.- P. 843-844. doi: 10.1345/a ph.18022.
84. Possible olanzapine-induced hepatotoxicity in a young Chinese patient / S. Y. Lui, S. Tso, M. Lam [et al.] // Hong Kong Med. J.- 2009.- Vol. 15, N 5.- P. 394-396.
85. Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity / D. Telles-Correia, A. Barbosa, H. Cortez-Pinto [et al.] // World J. Gastrointest. Pharmacol. Ther.- 2017.- Vol. 8, N 1.- P. 26-38. doi: 10.4292/wjgpt.v8.i1.26.
86. Quetiapine. [Электронный ресурс].- URL: http://livertox.nih.gov/Quetiapine.htm (дата обращения: 15.10.2016).
87. Quetiapine-associated cholestasis causing lipoprotein- X and pseudohyponatraemia / J. A. Klinke, S. C. Shapira, E. Akbari [et al.] // J. Clin. Pathol.- 2010.- Vol. 63, N 8.- P. 741-743. doi: 10.1136/ jcp.2008.064063.
88. Radzik J., Grotthus B., Leszek J. [Disorder of liver functions in a schizophrenic patient after long-term risperidone treatment - case report] // Psychiatr. Pol.- 2005.- Vol. 39, N2.- P. 309-313.
89. Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis / M. I. Lucena, N. Kaplowitz, H. Hallal [et al.] // J. Hepatol.- 2011.- Vol. 55, N4.- P. 820-827. doi: 10.1016/j.jhep.2010.12.041.
90. Relevance of liver enzyme elevations with four different neuroleptics: a retrospective review of 7,263 treatment courses / I. Gaertner, K. Altendorf, A. Batra [et al.] // J. Clin. Psychopharmacol.- 2001.- Vol. 21, N2.- P. 215-222.
91. Retrospective study of hepatic enzyme elevations in children treated with olanzapine, divalproex, and their combination / J. Gonzalez-Heydrich, D. Raches, T. E. Wilens [et al.] // J. Am. Acad. Child Adolesc. Psychiatry.- 2003.- Vol. 42, N 10.- P. 1227-1233. doi: 10.1097/00004583200310000-00014.
92. Risperidone. [Электронный ресурс].- URL: http://livertox.nih.gov/Risperidone.htm (дата обращения: 15.10.2016).
93. Risperidone and liver function tests in children and adolescents: a short-term prospective study / A. Erdogan, N. Atasoy, H. Akkurt [et al.] // Prog. Neuropsychopharmacol. Biol. Psychiatry.- 2008.- Vol. 32, N3.- P. 849-857. doi: 10.1016/j. pnpbp.2007.12.032.
Review
For citations:
Volkov V.P. Digestive system with antipsychotic therapy (literature review) Part VI: iatrogenic liver pathology (effect of atypical antipsychotics). Medical alphabet. 2017;4(40):33-37. (In Russ.)
Views:
348
Email this article 